Search
Search Results
##search.searchResults.foundPlural##
-
TREATMENT OUTCOMES AND CLINICAL RELEVANCE IN PATIENTS WITH DOUBLE EXPRESSOR DLBCL Sirapat Rungwittayatiwat1, Paisarn Boonsakan2, Pichika Chantrathammachart1, Teeraya Puavilai1, Sulada Pukiat1, Sithakom Phusanti1,3, Kochawan Boonyawat1, Pathawut Wacharapornin1, Pantep Angchaisuksiri1, Artit Ungkanont1,3, Suporn Chuncharunee1 Pimjai Niparuck1
1029PDF: 453HTML: 165 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3490PDF: 831HTML: 6693 -
HEMATOLOGY PATIENT PROTECTION DURING THE COVID-19 PANDEMIC IN ITALY: A NATIONWIDE NURSING SURVEY Hematology patient protection during the COVID-19
1510PDF: 545HTML: 212 -
MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS.
4553PDF: 1279HTML: 1884Untitled: 163Untitled: 161 -
UPDATE ON THE LABORATORY DIAGNOSIS OF INVASIVE FUNGAL INFECTIONS
2298PDF: 1347HTML: 1959 -
EFFECTS OF FACTOR XIII DEFICIENCY ON THROMBOELASTOGRAPHY. THROMBELASTOGRAPHY WITH CALCIUM AND LYSIS BY ADDITION OF STREPTOKINASE IS MORE SENSITIVE THAN SOLUBILITY TESTS
3083PDF: 931HTML: 1878Untitled: 149Untitled: 155Untitled: 146Untitled: 150Untitled: 139 -
CHLORAMBUCIL PLUS RITUXIMAB AS FRONT-LINE THERAPY IN ELDERLY/UNFIT PATIENTS AFFECTED BY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A SINGLE-CENTRE EXPERIENCE.
3019PDF: 853HTML: 1523Fig.1 CHL-R paper: 187Fig 2 CHL-R paper: 216 -
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
4193PDF: 1688HTML: 1094 -
CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: DIAGNOSTIC TOOLS, PROPHYLAXIS AND THERAPY
3941PDF: 1887HTML: 5190Table 1: 165 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2724PDF: 973HTML: 5494 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1279HTML: 361PDF: 785 -
NURSES’ PHYSICAL AND PSYCHOLOGICAL SYMPTOMS DURING THE FIRST COVID-19 LOCKDOWN IN ITALY A nationwide cross-sectional study in stem cell transplantation setting.
1592PDF: 792HTML: 216 -
Calreticulin mutation survey by high resolution melting method associated with unique presentations in essential thrombocythemic patients CALR mutation survey by HRM in ET patients
1179PDF: 690HTML: 250 -
HHVs AND LYMPHOPROLIFERATIVE DISORDERS
1326PDF: 783HTML: 3100 -
REGULATORY T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2250PDF: 935HTML: 7603Untitled: 253Fig2: 162Fig3: 142Fig4: 160 -
FLT3 Mutated Acute Myeloid Leukemia after CD19 CAR-T Cells
894PDF: 1179HTML: 88 -
BETA-GLOBIN GENE MUTATIONS IN TURKISH CHILDREN WITH BETA-THALASSEMIA: RESULTS FROM A SINGLE CENTER STUDY
1569PDF: 659HTML: 1606Beta-globin Gene Mutations in Turkish Children with Beta-Thalassemia: Results from a Single Center Study: 165 -
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1101PDF: 996HTML: 171 -
IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS
2968PDF: 830HTML: 7148Kost Fig1: 163Kost Fig 2: 153Kost Fig3: 149Kost Fig 4: 166Kost Fig5: 162Kost fig 6: 149 -
ANTIFUNGAL THERAPY IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
4640PDF: 1505HTML: 2226Untitled: 187Untitled: 202Untitled: 209Untitled: 191Untitled: 188 -
THE SYSTEMIC MASTOCYTOSIS: RADIOLOGICAL POINT OF VIEW Systemic mastocytosis
1400PDF: 508HTML: 646 -
CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL
3687PDF: 3032HTML: 182 -
UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)
3719Suppl. Files: 1029PDF: 1016Html: 104 -
-
IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY COVID-19 and hematologic malignancy
1342PDF: 707HTML: 189 -
GENETIC HETEROGENEITY OF BETA GLOBIN MUTATIONS AMONG ASIAN-INDIANS AND IMPORTANCE IN GENETIC COUNSELLING AND DIAGNOSIS
1698PDF: 1247HTML: 11431Figure1: 148Figure 2: 153 -
OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES
714PDF: 848Suppl. Files: 109HTML: 61 -
PERIPHERAL NERVOUS SYSTEM INVOLVEMENT IN LYMPHOPROLIFERATIVE DISORDERS
1685PDF: 846HTML: 357Fig1: 211Fig.2: 228Fig. 3: 159Fig. 5: 165Fig. 4: 196 -
CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA CAR-T and CLL
3368PDF: 1441HTML: 63 -
ALLOGENEIC TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA
1311PDF: 728HTML: 930 -
IS IT POSSIBLE TO PREDICT TUMOR PROGRESSION THROUGH GENOMIC CHARACTERIZATION OF MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA? MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA
2476PDF: 1083HTML: 120 -
CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA CAR T Cells and Myeloma Treatment
1639PDF: 786HTML: 137 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
3952PDF: 1007HTML: 3555Untitled: 162Cneo. Fig.1: 96Untitled: 88Untitled: 109Untitled: 110







